Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Authors :: Ekkehard Mössner
Marina Bacac
Pablo Umana
Christian Klein
Günter Fingerle-Rowson
Source :: Successful Drug Discovery
Publication Year :: 2018
Publisher :: Wiley-VCH Verlag GmbH & Co. KGaA, 2018.

Subjects :: chemistry.chemical_compound
Anti cd20 antibody
chemistry
business.industry
Obinutuzumab
Chronic lymphocytic leukemia
Cancer research
Medicine
Hodgkin lymphoma
business
medicine.disease
Cancer treatment

Full Text Access

Tools